Deep knowledge on
small-molecule drugs and
the 90,000 global patents
covering them

Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: MAXALT

« Back to Dashboard
Maxalt is a drug marketed by Merck and is included in two NDAs. It is available from six suppliers.

The generic ingredient in MAXALT is rizatriptan benzoate. There are twenty-two drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the rizatriptan benzoate profile page.

Summary for Tradename: MAXALT

Suppliers / Packagers: see list12

Clinical Trials for: MAXALT

Drug Study in Pediatric Subjects With Migraines (MK0462-083 AM1)
Status: Completed Condition: Migraine Disorders

Study of Rizatriptan in the Treatment of Acute Attacks of Post-traumatic Headache in U.S. Military Troops
Status: Withdrawn Condition: Chronic Post-traumatic Headache

Maxalt 10mg Plus Caffeine 75mg in the Acute Treatment of Migraine Headache
Status: Completed Condition: Migraine With Aura; Migraine Without Aura

Long-Term Exposure to Rizatriptan 5-mg and 10-mg Oral Tablet (Combined Extension Protocols MK-0462-022, MK-0462-025, MK-0462-029)
Status: Completed Condition: Migraine Disorders

A Study to Evaluate the Efficacy and Tolerability of Rizatriptan for Treatment of Acute Migraine in Children and Adolescents (MK-0462-082 AM7)
Status: Completed Condition: Migraine, Acute

Rizatriptan 5 mg and 10 mg, Sumatriptan 100 mg, and Placebo Comparison Study (0462-030)
Status: Completed Condition: Migraine Headache

Two Rizatriptan Prescribing Portions for Treatment of Migraine
Status: Completed Condition: Migraine

Rizatriptan for Episodic Dizziness in Vestibular Migraine
Status: Recruiting Condition: Vestibular Migraine; Migrainous Vertigo

A Study to Evaluate the Safety and Tolerability of Rizatriptan for Long Term Treatment of Acute Migraine in Children and Adolescents (MK-0462-086 AM3)
Status: Completed Condition: Acute Migraine With or Without Aura in Adolescents

A Study of Rizatriptan for the Treatment of Acute Migraine in Patients on Topiramate for Migraine Prophylaxis
Status: Completed Condition: Migraine

Courtesy of
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
rizatriptan benzoate
TABLET;ORAL020864-001Jun 29, 1998RXNo<disabled><disabled>
rizatriptan benzoate
TABLET, ORALLY DISINTEGRATING;ORAL020865-002Jun 29, 1998RXYes<disabled><disabled>
rizatriptan benzoate
TABLET;ORAL020864-002Jun 29, 1998RXYes<disabled><disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: MAXALT

Drugname Dosage Strength RLD Submissiondate
rizatriptan benzoateOrally Disintegrating Tablets5 mg and 10 mgMaxalt-MLT2/17/2006
rizatriptan benzoateTablets5 mg and 10 mgMaxalt9/2/2004
« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013   2014  

For more information try a trial or see the database preview and plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2015 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn